Assignee
NOVIMMUNE SA
CH·48 granted patents·23 pending applications·454 citations·filing 1998–2024
Top patents by PatentIndex Score
71 records- 0198US7728114B2Anti-CD3 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2005·Granted Jun 1, 2010·260 cites·25 claims
- 0293US8034344B2Anti-IL-6/IL-6R antibodies and methods of use thereofNOVIMMUNE SA·Filed 2009·Granted Oct 11, 2011·19 cites·6 claims
- 0393US7700098B2Anti-interferon gamma antibodies and methods of use thereofNOVIMMUNE SA·Filed 2006·Granted Apr 20, 2010·19 cites·9 claims
- 0493US7674884B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2005·Granted Mar 9, 2010·15 cites·3 claims
- 0592US9926382B2Methods for the generation of multispecific and multivalent antibodiesNOVIMMUNE SA·Filed 2013·Granted Mar 27, 2018·16 cites·12 claims
- 0691US7786268B2Anti-IP-10 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2008·Granted Aug 31, 2010·14 cites·11 claims
- 0791US7744884B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2007·Granted Jun 29, 2010·11 cites·12 claims
- 0890US10759862B2Anti-IL-6/IL-6R antibodies and methods of use thereofNOVIMMUNE SA·Filed 2017·Granted Sep 1, 2020·3 cites·6 claims
- 0989US12448444B2Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereofNOVIMMUNE SA·Filed 2022·Granted Oct 21, 2025·2 cites·35 claims
- 1089US11260117B2Anti-CD47 x anti-mesothelin antibodies and methods of use thereofNOVIMMUNE SA·Filed 2018·Granted Mar 1, 2022·4 cites·18 claims
- 1189US9682142B2Anti-interferon gamma antibodies and methods of use thereofNOVIMMUNE SA·Filed 2013·Granted Jun 20, 2017·9 cites·10 claims
- 1289US7312320B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2004·Granted Dec 25, 2007·20 cites·14 claims
- 1388US9688755B2Fc receptor-binding polypeptides with modified effector functionsNOVIMMUNE SA·Filed 2013·Granted Jun 27, 2017·8 cites·7 claims
- 1486US10047144B2Methods of purifying antibodiesNOVIMMUNE SA·Filed 2012·Granted Aug 14, 2018·8 cites·8 claims
- 1585US9850304B2Anti-CD3 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2013·Granted Dec 26, 2017·5 cites·3 claims
- 1684US9828430B2Anti-IL-6/IL-6R antibodiesNOVIMMUNE SA·Filed 2016·Granted Nov 28, 2017·3 cites·4 claims
- 1783US9234034B2Methods of treating autoimmune diseases using anti-IL6/IL-6R complex antibodiesNOVIMMUNE SA·Filed 2012·Granted Jan 12, 2016·4 cites·5 claims
- 1881US10759858B2Anti-CD3 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2017·Granted Sep 1, 2020·1 cites·14 claims
- 1980US10457749B2Methods of purifying bispecific antibodiesNOVIMMUNE SA·Filed 2016·Granted Oct 29, 2019·4 cites·16 claims
- 2078US11203646B2Anti-CD3 epsilon antibodies and methods of use thereofNOVIMMUNE SA·Filed 2019·Granted Dec 21, 2021·1 cites·24 claims
- 2178US10689441B2Anti—TLR4 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2014·Granted Jun 23, 2020·4 cites·19 claims
- 2278US10597465B2Methods for the generation of multispecific and multivalent antibodiesNOVIMMUNE SA·Filed 2017·Granted Mar 24, 2020·1 cites·5 claims
- 2378US10023646B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2017·Granted Jul 17, 2018·1 cites·8 claims
- 2478US2024400720A1Anti-cd47 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2024·Application pending·0 cites
- 2576US9540444B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2013·Granted Jan 10, 2017·1 cites·6 claims
- 2675US10556960B2Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkersNOVIMMUNE SA·Filed 2017·Granted Feb 11, 2020·2 cites·18 claims
- 2774US11613582B2Anti-IL-6/IL-6R antibodies and methods of use thereofNOVIMMUNE SA·Filed 2020·Granted Mar 28, 2023·0 cites·2 claims
- 2874US10421809B2Anti-TLR4 antibodies and uses thereofNOVIMMUNE SA·Filed 2016·Granted Sep 24, 2019·2 cites·8 claims
- 2974US10400044B2Anti-TLR4 antibodies and uses thereofNOVIMMUNE SA·Filed 2016·Granted Sep 3, 2019·1 cites·17 claims
- 3074US9512221B2Anti-TLR4 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2014·Granted Dec 6, 2016·3 cites·6 claims
- 3174US2022324994A1Anti-tlr4 antibodies and uses thereofNOVIMMUNE SA·Filed 2021·Application pending·0 cites
- 3273US11059910B2Anti-CD47 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2013·Granted Jul 13, 2021·1 cites·7 claims
- 3372US9815909B2Readily isolated bispecific antibodies with native immunoglobulin formatNOVIMMUNE SA·Filed 2013·Granted Nov 14, 2017·1 cites·10 claims
- 3472US9650437B2Nucleic acid encoding and method of producing anti-IL-17A/IL-17F cross-reactive antibodiesNOVIMMUNE SA·Filed 2013·Granted May 16, 2017·1 cites·20 claims
- 3572US9475873B2Nucleic acids encoding anti-IL-17F antibodies and methods of use thereofNOVIMMUNE SA·Filed 2014·Granted Oct 25, 2016·1 cites·13 claims
- 3672US9453076B2Anti-TLR4 antibodies and uses thereofNOVIMMUNE SA·Filed 2013·Granted Sep 27, 2016·1 cites·13 claims
- 3772US6800469B1Methods for diagnosis and therapy of autoimmune disease, such as insulin dependent diabetes mellitus, involving retroviral superantigensNOVIMMUNE SA·Filed 2000·Granted Oct 5, 2004·5 cites·4 claims
- 3871US2021009691A1Anti-cd3 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2020·Application pending·0 cites
- 3970US10982004B2Anti-TLR4 antibodies and uses thereofNOVIMMUNE SA·Filed 2019·Granted Apr 20, 2021·0 cites·11 claims
- 4070US2025171537A1Method of treating disease using anti-cd47 x anti-mesothelin antibodies as a sole agent and in combination with anti-pd-1 antibodiesNOVIMMUNE SA·Filed 2024·Application pending·0 cites
- 4169US10844132B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2018·Granted Nov 24, 2020·0 cites·8 claims
- 4268US9688769B2Methods and compositions for diagnosis and treatment of disorders in patients with elevated levels of TLR4 ligands and other biomarkersNOVIMMUNE SA·Filed 2014·Granted Jun 27, 2017·2 cites·18 claims
- 4364US9534049B2Neutralizing antibodies and methods of use thereofNOVIMMUNE SA·Filed 2013·Granted Jan 3, 2017·0 cites·10 claims
- 4464US2020231707A1Readily isolated bispecific antibodies with native immunoglobulin formatNOVIMMUNE SA·Filed 2019·Application pending·0 cites
- 4563US11840553B2Anti-CD47 antibodies and methods of use thereofNOVIMMUNE SA·Filed 2018·Granted Dec 12, 2023·0 cites·2 claims
- 4663US2024254223A1Reciprocally masked antibody-cytokine fusion proteins and methods of use thereofNOVIMMUNE SA·Filed 2023·Application pending·0 cites
- 4762US2020239566A1Anti-tlr4 antibodies and uses thereofNOVIMMUNE SA·Filed 2019·Application pending·0 cites
- 4861US10494446B2Readily isolated bispecific antibodies with native immunoglobulin formatNOVIMMUNE SA·Filed 2017·Granted Dec 3, 2019·0 cites·7 claims
- 4961US2025075000A1Combination therapy with a cea x cd28 bispecific antibody and blocking anti-pd-1 antibodies for enhanced in vivo anti-tumor activityNOVIMMUNE SA·Filed 2024·Application pending·0 cites
- 5060US2023295348A1Composition and methods for the selective activation of cytokine signaling pathwaysNOVIMMUNE SA·Filed 2023·Application pending·0 cites
Showing the top 50 of 71 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when NOVIMMUNE SA files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →